Different works recently showed a potential benefit of administering hematopoietic growth factors such as stem cell factor (SCF), granulocyte colony-stimulating factor (G-CSF), and their combination in the acute, subacute, and even chronic phase of ischemic stroke in animal models [135–138]. Here, KITLG is linked to ischemic stroke.